

Remarks

The Specification has been amended to perfect the claim to priority made in the PCT application, as required under 35 U.S.C. § 119(e).

The Specification has also been amended to add an abstract as required under 37 U.S.C. § 1.72(b). This abstract is identical to the abstract filed with PCT Application.

The Claims have been amended to place them in proper form as acceptable under US patent law. Namely, the nested multiply dependent claims have been amended to remove dependency on other multiply dependent claims and “use style” and “Swiss style” claims have been deleted in favor of the corresponding method of treatment claims.

Also, Claim 1 has been amended as it was amended in response to the international examination, limiting R⁹ to hydrogen. This amendment is supported by the specification (see page 35, line 24 of the PCT Specification as filed) and original claims (original Claim 14, now cancelled), as was pointed out in the PCT Article 34 amendment.

No new matter has been added through any of these amendments.

Entry of these preliminary amendments prior to examination of the application is requested.

Respectfully submitted,

/s/ R. Craig Tucker
Attorney for Applicants
Registration No. 45,165
Phone: 317-433-9829

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

July 18, 2006